|
|
Article: FDA Approves New Use for Micardis[R] in Cardiovascular Risk Reduction and Twynsta[R] as New Combination Treatment for High Blood Pressure.
- Article from:
- Heart Disease Weekly
- Article date:
- November 8, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis=AE (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998. ...
Related newspaper, magazine, and journal articles:
|
|
Article: BI's Micardis shows good metabolic profile.(Boehringer ...
Pharma Marketletter;
September 12, 2005 ;
700+ words
... ... Preclinical studies link the metabolic benefit of Boehringer Ingelheim's blood pressure lowering drug Micardis (telmisartan) to ... components of metabolic syndrome, such as high blood pressure, but we need to tackle the different risk ...
|
|